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Behc¸et’s disease (BD) is a chronic relapsing vasculitis that affects vessels of all types and sizes with a broad spectrum of phenotypic
heterogeneity and complex immunopathogenesis. Efforts by the scientific community to resolve the unmet needs of BD and gaps
in our knowledge have been hampered by considerable challenges that primarily relate to the rare nature of the disease in many
parts of the world and its heterogeneity. Controversies remain in many aspects of the disease including the diagnostic criteria,
immunopathogenesis and biomarker discovery, geographical variation, and therapeutic considerations. In this review, we highlight
recent advances in our scientific understanding of BD, shed new insights into diagnostic and treatment strategies, and discuss
residual gaps in our knowledge that will serve as the basis for current and future research.
1. Introduction
Behc¸et’s disease (BD), also known as the Silk Road disease
[1], was first described in the Cyclades island of Kos by
Hippocrates in his writings Third Book of Endemic Diseases
[2, 3] but remained in relative obscurity for more than
two millennia until 1937 when a Turkish dermatologist in
Istanbul, Hulusi Behc¸et, described a trisymptom complex
of recurrent aphthous stomatitis, genital ulcers, and iritis in
three native Eastern Mediterranean patients and posited a
new clinical syndrome [4].
Previously described among populations extending
around the ancient Silk Road, a trading route that stretched
from the Iberian Peninsula on the southwestern tip of
Europe, across Iran, Iraq, and Syria of the Middle East to
the Far East, BD has a global distribution and can be seen
throughout the world including countries further north
and south of the equator (≥60∘). The principle morbidity
of BD relates to its vascular, ophthalmic, and neurological
complications, and if left untreated, it may lead to blindness
and death.
In this review article, we explore recent studies that
have substantially contributed to our understanding of BD
in recent years and have provided new insights into the
epidemiology, etiology, immunopathogenesis, clinical man-
ifestations, classification criteria, and management strategies
of BD as well as identifying areas for further research.
2. Epidemiology
Behc¸et’s disease is mainly seen along the ancient Silk Road
which stretched from the Far East to the Mediterranean
Sea but has an occurrence worldwide. Turkey has the
highest prevalence with studies reporting wide prevalence
rates between 602 and 20 per 100,000 population, followed
by Iran with 68 per 100,000 population (Table 1) [5–26].
The frequency increases in a north-to-south manner within
the European continent [9, 27]. In Northern Europe, the
prevalence ranges from 0.64 to 4.94 per 100,000 population
[5–8]. It is noted that the prevalence has increased over
time, which may relate to better awareness and/or migration
[23, 24].
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Table 1: The worldwide prevalence of BD.
Country/area Study (year) Patients (𝑛) Population/ participants Prevalence(per 100,000)
Northern Europe
UK (Yorkshire) Chamberlain (1977) [5] 32 5,000,000 0.64
Scotland Jankowski et al. (1992) [6] 15 5,500,000 0.3
Ireland (Dublin) Kilmartin et al. (1997) [7] 24 1,058,264 2.27
Sweden (Skane) Mohammad et al. (2013) [8] 40 809,317 4.94
Europe
Germany Papoutsis et al. (2006) [9] 165 3,391,344 4.87
France (Paris) Mahr et al. (2008) [10] 79 1,094,412 7.1
Italy (Rome) Valesini et al. (1991) [11] 155 NA 19
Greece Kaklamani et al. (2000) [12] 90 NA 11
Mediterranean
Turkey
Tokat Bas¸ et al. (2016) [13] 14 2,325 602
Kayseri C¸o¨lgec¸en et al. (2015) [14] 9 5,218 170
Havsa Cakir et al. (2004) [15] 1 4,861 20
Istanbul Azizlerli et al. (2003) [16] 101 23,986 420
Ankara Idil et al. (2002) [17] 16 17,256 110
Ordu Yurdakul et al. (1988) [18] 19 5,121 370
Istanbul Demirhindi et al. (1981) [19] 4 4,940 80
Mediterranean
Iran Davatchi et al. (2007) [20] 7 10,291 68
Egypt Assaad-Khalil et al. (1997) [21] 274 NA 16
Jordan Madanat et al. (2000) [22] 200 NA 27
Others
US (Olmsted County) Calamia et al. (2009) [23] 13 144,248 5.2
Japan Nakae et al. (1993) [24] 3316 NA 13.5
Korea Bang et al. (2011) [25] 15,554 NA 30.2
China Zhang et al. (2006) [26] 1996 NA 14
Previously thought to have an equal sex distribution, BD
appears to have a male preponderance in Turkey [13, 14, 16],
the Middle East, and Central Europe [28]; however, females
predominate in Northwest Europe [5, 6] and the Far East
[24–26, 29, 30]. Certain regional/geographical differences
may exist; for example, pathergy phenomenon and ocular
lesions are less commonly seen in the West [31–33], while
gastrointestinal manifestations are more commonly seen in
the Far East [34].
3. Etiology
The cause of BD remains largely unknown but it has been
postulated that when a genetically predisposed or susceptible
population is exposed to undetermined exogenous agents,
this triggers dysregulation of both autoinflammatory and
autoimmune responses resulting in multisystem vasculitis
with distinct clinical characteristics. However, so far, no
microbiologic or external environmental exposure has been
consistently identified as a risk factor or trigger [35, 36].
More recently, dysbiosis of gut microbiota characterized by
the reduction of themicrobiota diversity and composition has
been implicated in several autoimmune disorders including
diseases outside of the gut [37, 38], and this dysbiosis seems
to play a role in the pathogenesis of BD [39, 40].
Association of HLA-B∗51 allele is well recognized as the
strongest genetic susceptibility gene so far among genetically
predisposed BD patients [41, 42]. However, some studies
have failed to demonstrate linkage [6, 42, 43], while certain
indigenous Amerindians have a high prevalence of HLA-
B∗51, but with no reported cases of BD [44]. A high level of
recombination within the MHC is known to have occurred
in these eastern populations before their migration. It was
suggested that the disruption of genetic loci in linkage
disequilibria within HLA-B∗51 might be one reason for the
absence of disease in these high HLA-B∗51-bearing popula-
tions [44].
Centromeric regions including the tumour necrosis fac-
tor (TNF) gene and the MHC class I chain-related gene A
(MICA) polymorphisms have been the focus of considerable
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research, particularly since TNF exerts a profound effect
on the immune response, and MICA has a putative role
in nonclassical antigen presentation at mucosal surfaces.
However, it has become apparent that polymorphic areas in
these regions, which are associated with BD, are in fact raised
as a consequence of linkage disequilibriumwithin HLA-B∗51
and may provide little independent contribution to disease
in HLA-B∗51-negative individuals.Thus, inmost populations
the highest risk factor for BD is still in or close to the HLA-
B∗51 region [44].
4. Immunopathogenesis
Evidence suggests that a divergent and complex series
of interactions and interplay between different cytokines,
chemokines, and various components of the host immune
system is involved in the pathogenesis of BD [45, 46]. There
are several established cytokines such as TNF-𝛼, interferon-
gamma (IFN-𝛾), interleukin-1 beta (IL-1𝛽), IL-6, IL-10, IL-
17, and IL-23 known to be involved [45–47]. Furthermore,
several “novel” cytokines are now implicated in the patho-
genesis of BD including IL-2, IL-12, IL-21, IL-22, IL-33, and
IL-37 [45, 48–59]; however, these require further studies to
support a definitive role. Some of these findings have been
replicated in the genome-wide association studies (GWAS)
[60–64]. Moreover, the successful use of several anticytokine
therapies in BD patients has provided additional evidence
that cytokines play a crucial role in its pathogenesis [45, 46].
There is emerging evidence to support upregulation of
chemokines in patients with BD [65–69], and a number
of studies have implicated regulatory T cells (Tregs) and
gammadelta (𝛾𝛿) T cells in the immunopathogenesis of BD
[70–73]. In addition, studies have also supported a role for
neutrophil hyperfunction, endothelial cell activation [74–
76], and activation of inflammasomes-dependent [77, 78]
and JAK/STAT pathways [79, 80], while other studies have
demonstrated correlations between autoantibodies such as
anti-saccharomyces cerevisiae antibodies (ASCA) and anti-
endothelial cell antibodies (AECA) and BD [81–86].
5. Clinical Manifestations
Commonly the symptoms of BD are self-limiting and tend to
relapse in anunpredictablemannerwith differing phenotypes
presenting among individuals but certain manifestations
such as ocular, vascular, and neurological manifestationsmay
lead to significantmorbidity and death. Ideguchi et al. in their
study in a Japanese population found that the time between
the initial symptoms to the time of diagnosis was 8.6 years
[87].
Oral aphthosis is the most common clinical feature and
is usually the first manifestation [33]. It is characterized by
round to oval ulceration with a white or yellowish necrotic
base and surrounded by erythematous halo [88, 89]. It may
involve any part of the oralmucosa, frequently the lips, buccal
mucosa, tongue, gingiva, palate, and tonsils [33] and can
be induced by local trauma such as after dental treatment
(mucosal pathergy equivalent) [89]. The rate of recurrence
and duration can vary with each attack and the majority of
episodes are significantly painful [89]. Genital ulceration is
the second most common observed feature of BD [33] and
can occur on the scrotum, prepuce, glans, and shaft and tip of
the penis in men, while it is typically seen on the vulva (labia
majora, labia minora, and mons pubis) and/or intravaginal
and cervical areas in women. They can also occur on the
perianal, perineal, and groin areas. The ulcers are usually
well defined, deep, and often painful and heal slowly with
the larger and deeper lesions frequently healing with scarring
[89].
The eye is the most common vital organ involved in
BD [90] and over two-thirds of patients will develop ocu-
lar inflammation, most often bilateral panuveitis or reti-
nal vasculitis [91]. Ocular manifestations include nongran-
ulomatous iridocyclitis, chorioretinitis, or residual lesions
suggesting previous iridocyclitis or chorioretinitis such as
posterior synechia, complicated cataracts, lens pigmentation,
chorioretinal atrophy, optic nerve atrophy, and secondary
glaucoma. The prognosis is worse among patients with
posterior segment involvement. Hypopyon in BD classically
is nonsticky, forms a niveau, and tends to shift according to
the head positioning [92]. Vision loss develops and worsens
with each uveitis attack.
Skin manifestations are also one of the most common
features of BD and these include but are not limited to
erythema nodosum like eruptions, pseudofolliculitis, and
papulopustular lesions. Despite being considered as one of
the milder symptoms, skin manifestations may contribute
to significant morbidity and impact negatively on patients’
quality of life. Vascular BD affects both arteries and veins
of all sizes and is more common in men than women [93].
Thrombophlebitis affecting superficial or deep veins is the
most common manifestation, while arterial disease is less
frequent but a major cause of mortality in BD patients.
Neurological manifestations are relatively uncommon and
can be classified into parenchymal (an inflammatory menin-
goencephalitic process with presence of isolated brainstem
atrophy as a powerful discriminator) or nonparenchymal
(secondary to vascular involvement) [94]. Diagnosis is dif-
ficult and often MRI brain (including contrast and MR
venogram) and cerebrospinal fluid (evidence of neutrophilia
and/or pleocytosis, frequently absent oligoclonal bands, and
normal glucose levels) may assist in the diagnosis [94]. Other
known manifestations include arthritis/arthralgia, cardiac,
gastrointestinal, and laryngeal involvement [33, 95].
Pathergy phenomenon is a nonspecific cutaneous hyper-
reactivity response to minor trauma.There is large geograph-
ical variability in the prevalence of a positive pathergy test
reaction [33, 96], and a decline in the positive rate over time
has been detected [33, 97]. Positive pathergy testing is as high
as up to 77% among patients in the Middle East, around the
Mediterranean and the Far East [33, 98], but is less common
in Northern European countries and the USA [43, 99–101].
6. Classification Criteria
The diagnosis of BD is clinical but not all symptoms occur
simultaneously and the evolution varies among patients as
well as among cohorts from different geographical areas.
4 International Journal of Rheumatology
Furthermore, there is no laboratory test that can be used to
make the diagnosis, hence the need for developing diagnostic
disease criteria. The first diagnostic criteria in BD were
devised in 1946 [102, 103], and now there are at least 17
diagnostic criteria available [103].
In 1990, the International Study Group (ISG) set the
classification criteria [104] which were presented at the
6th International Conference on BD in Paris (1993) where
recurrent oral aphthosis three or more times in a year is
mandatory, with the presence of any two of the following:
genital ulceration, ocular or cutaneous manifestations, or
skin pathergy. It is important to note that the criteria are
applicable only if no other clinical explanation is present.
Despite being of high specificity and recognizing its con-
tribution to assisting comparison among cohorts across the
world in a more standardized manner, the criteria raised
several important issues including the exclusion of minority
groups of likely BD patients without the oral aphthosis and
demonstrating relatively lower sensitivity in comparison to
other diagnostic criteria [105].
To overcome these issues, in 2004 during the 11th
International Conference on BD in Antalya, Turkey, The
International Team for the Revision of the ISG criteria was
formed involving 27 countries for the revision, proposal, and
creation of the newer international criteria for BD (ICBD),
which was then revised in 2010 [103].These criteria are based
on a point basis, oral aphthosis is notmandatory, and vascular
and neurological manifestations were added to the existing
five items of the ISG criteria. While oral aphthosis, genital
ulceration, and eye manifestations were given two points,
other remaining items were given one point each; getting
four or more points confirms the diagnosis. It demonstrates
improved sensitivity (97% versus 77.5%), a similar specificity
(97% versus 99%), and better accuracy (97 versus 87%) when
compared to the ISG criteria [103].
7. Current Management Strategies
Effective long-term management in BD patients is often
challenging and requires a coordinated multidisciplinary
approach. The cornerstone of treatment in systemic BD
includes corticosteroids together with steroid-sparing agents
(conventional immunomodulators and/or biological thera-
pies) tailored upon the pattern and severity of patient’s symp-
toms, mainly to achieve rapid resolution of inflammatory
attacks, prevention of relapsing episodes, preservation of vital
organs, and overall improvement in patients’ quality of life.
7.1. Conventional Treatments
7.1.1. Corticosteroids. Topical steroid therapy such as triamci-
nolone oral paste with or without topical anesthetics has been
shown to be very useful for oral aphthosis in BD [106, 107].
Short courses of systemic oral or depot corticosteroids are
particularly useful and effective in oral aphthosis resistant
to topical treatment [108, 109] and controlling erythema
nodosum especially in female BD patients [110]. High-
dose pulsed intravenous methylprednisolone is reserved for
patients with threatened vital-organ function. The European
League Against Rheumatism (EULAR) task force recently
in June 2016 presented their updated recommendations for
managing BD at the 17th Annual European Congress of
Rheumatology in London and recommended systemic cor-
ticosteroid as a combination therapeutic option in inflamma-
tory ocular, vascular (including arterial aneurysms and acute
deep vein thrombosis), gastrointestinal, or nervous system
involvement [111]. Prolonged and frequent use of systemic
corticosteroid however is associatedwith various unfavorable
side effects.
7.1.2. Colchicine. Being one of the oldest known drugs,
colchicine has been proven to be beneficial in several ran-
domized controlled trials in the less severe manifestations
of BD patients including arthralgia, erythema nodosum, and
genital ulcers [112, 113]. The EULAR task force in 2016 also
recommended colchicine as first-line treatment for arthritis
in BD patients [111]. Its early use however does not decrease
the need to use immunosuppressive drugs in the long term
[114].
7.1.3. Conventional Immunomodulators. Frequently the addi-
tional use of a conventional immunomodulator as adjunctive
or as steroid-sparing therapy is required. This is of utmost
importance especially in countries with limited access to bio-
logical therapy. Agents such as methotrexate, azathioprine,
mycophenolate mofetil, and cyclophosphamide have been
shown to be beneficial [115–121] to induce and maintain
remission. Cyclosporine and thalidomide are also options;
however, cyclosporine has been strongly associated with
neurological complications [122, 123], while thalidomide is
highly neurotoxic and teratogenic and should be used with
extreme caution if at all in women of childbearing age now
that more modern therapies are available [124].
7.2. Biological Therapy. Emerging insights into the immuno-
pathogenesis of BD have led to novel and more specific
therapeutic targets. The advent of biological therapies has
revolutionized the treatment of BD offering more tailored
therapies resulting in significantly better disease control and
prolonged remission in the majority of patients. This is an
area that is rapidly expanding and is currently being robustly
explored by both clinicians and researchers across the globe.
Anti-TNFs have been shown to be remarkably effective
and relatively safe [125, 126].Nonetheless, despite twodecades
of experience in rheumatological conditions such as BD,
there are still many debatable issues surrounding their use
including the following: (1) When to start treatment and
the duration of treatment and does early use modulate the
subsequent clinical course? (2) Is it beneficial to coadminister
conventional nonbiologic DMARDs such as methotrexate
to reduce immunogenicity and to reduce secondary failure
rates? (3) The infection rates for combination therapy are
especially high in elderly patients. (4) How effective are
the “newer” anti-TNFs such as certolizumab pegol and
golimumab? (5) Head-to-head studies to compare the safety
and efficacy of different groups of biological agents, espe-
cially anti-TNF and interferon-2-alpha as monotherapy or
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in combination with conventional immunomodulators, are
required.
Interferons (IFNs) are the oldest known cytokine and
type-I IFN has been used as one of the treatment modalities
in BD as early as the mid-1980s [127, 128]. There is gathering
evidence, especially in more recent times, documenting the
successful use of both IFN-𝛼-2a and -2b with acceptable
toxicity profiles in many clinical trials [129–133]. Contrary to
IL-1𝛼, IL-1𝛽 is not present in cells from healthy individuals
[134] and has been demonstrated to be one of the principal
highly active proinflammatory cytokines involved in the
pathogenesis of BD [45–47]. There is emerging theoretical
evidence for the use of IL1𝛽-regulating antibody agents
such as Gevokizumab [135, 136], Anakinra [137–140], and
Canakinumab [141–144] in BD, and another orphan drug
from this group Rilonacept has been successfully used in
other autoinflammatory syndromes [145, 146].
Despite looking promising in the treatment of neuro-
BD [147–152], the use of IL-6 blockade-Tocilizumab has
yielded less convincing results than anticipated [152–155]
and a controlled clinical trial for further evaluation of this
biological agent has been terminated due to low enrollment
[156]. Another humanized monoclonal antibody of IgG1
CAMPATH-1H-Alemtuzumab has been successfully used
in refractory BD [157–159]. Other biological agents that
are currently or have previously been considered worthy
of consideration in the treatment of BD include the IL-
12/23 monoclonal antibody-Ustekinumab [160, 161], B-cell
depletion antibodies-Rituximab [162–166], Belimumab, and
the competitive binding to CD80 and CD86 costimulator
antibody-Abatacept which is currently undergoing an open-
label clinical trial in the treatment of mucocutaneous mani-
festations of BD [167].
There are also “less successful” biological agents in BD:
the IL-17A blockade by subcutaneous (SC) Secukinumab
therapy failed to meet its primary endpoints in three ran-
domized controlled clinical trials which involved 118 Behc¸et’s
uveitis patients [168]; however, Letko et al. [169] argued that
the dose and the mode of administration may have been a
confounding factor and suggested in their proof-of-concept
study a higher dose and a different route of administration
of Secukinumab (from 300mg SC to intravenous admin-
istration of 30mg/kg and 10mg/kg). Another monoclonal
antibodyDaclizumab, an IL-2 receptor antagonist, also failed
to demonstrate efficacy in Behc¸et’s uveitis patients compared
to placebo [170] despite demonstrating potent efficacy in
many previous studies for other causes of noninfectious
uveitis [171–173], while evidence for treatment with intrav-
itreal Bevacizumab, a vascular endothelial growth factor A
antibody to treat inflammatory ocular manifestations, has
been conflicting [174–178].
7.3. Novel Nonbiologic Small Molecules. Apremilast, a novel
small molecule that selectively inhibits phosphodiesterase
4 (PDE4) which is currently approved for psoriasis and
psoriatic arthritis, has been shown in a randomized, double
blind, placebo-controlled phase 2 study to be effective in
treating oral ulcers in BD patients [179]. It is currently under-
going subsequent phase 3 trials. The demonstration of Janus
kinase-1/signal transducers and activators of transcription-3
(JAK1/STAT3) signaling pathway activation in BD [79] sug-
gests a potential role for JAK inhibitors (Jakinibs) as a possible
next-generation therapeutic modality in the management of
BD.
8. Controversies, Conundrums, and Chasms:
Prospects for Further Research
BD has been the subject of extensive investigation since its
first formal description approximately 80 years ago. Despite
best efforts, controversies continue to exist and several
questions in many aspects of BD remain unanswered. The
17th International Conference on BD held in Matera, Italy, in
September 2016 was a unique opportunity to reflect on the
residual challenges that remain in BD and also to highlight
new advances in research from the scientific community
across the world.
The main areas where controversies continue to exist
relate to (1) diagnostic criteria, (2) immunopathogenesis and
the search for biomarkers, (3) regional and geographical
phenotypic and genotypic variability, and (4) therapeutic
considerations including the use of biological therapies and
the role of anticoagulation in thrombosis.
One of the major challenges still faced by clinicians
is the diagnostic dilemma due to the wide spectrum or
heterogeneity of disease manifestations with varying sever-
ity, the unpredictable relapsing and remitting episodes of
most patients, and the variable chronological evolution of
symptoms between different individuals. Despite recognizing
mucocutaneous lesions as the hallmark of the disease with
ocular inflammation and skin lesions considered part of the
major symptoms, a discreet subset of patients manifests other
less common yet important characteristics such as vascular,
neurological, gastrointestinal, and laryngeal disease. Besides
the controversy regarding the optimalmanagement approach
among this discreet subset of patients, these infrequent
manifestations may lead to significant delay in diagnosis
resulting in irreversible organ damage for the patient.
A closely related issue that remains a research enigma is
the lack of sensitive and specific diagnostic laboratory tests
to confirm or support the final diagnosis of BD. Until we
discover such biomarkers, the burden of diagnosis remains
with the clinician’s ability to recognize and collate a diverse
spectrum of presentingmanifestations. A substantial number
of patients with BD remain undiagnosed for many years
resulting in a significant increase in morbidity, disability, and
worsening quality of life.
One possible solution to this dilemma is to broaden the
classification criteria combining both objective clinical indi-
cators and biomarkers. However, despite the emergence of a
number of potential candidate biomarkers, there is still a lack
of sufficient evidence to support their implementation and
incorporation into the contemporary classification criteria. In
the era of precision medicine, this area provides a significant
opportunity for improvement in the diagnostic criteria and to
find early predictors to detect cohorts with a severe aggressive
disease phenotype. Better understanding of disease pathways
and the continuous search for signaturemarkers may provide
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novel insights into early detection of the disease in the future
and providing potential targets for novel therapeutic agents
so patients may be treated with the best treatment option in
a timely manner.
One of the groundbreaking discoveries of late is the
recognition that BDmay be diagnosed solely based on ocular
findings alone in the absence of systemic manifestations [90]
using the state-of-the-art imaging technologies, and this is
extremely important as ocular manifestation may be the first
presenting manifestations in 10–15% of BD patients [180].
The ultimate goal in eye disease is to sustain remission with
preservation of vision [91]. Recent studies support earlier and
more frequent consideration for biological therapy inBehc¸et’s
uveitis [91] but questions remain regarding when to use
them in patients with uveitis alone and with classical uveitis
characteristics but not fulfilling the international criteria for
BD. Steroids, while able to rapidly control acute flares, are
not able to reduce recurrence rates and their prolonged use
is associated with serious side effects.
Recent attention has also focused on the presence of
racial, geographical, or regional predilection in phenotypic
heterogeneity and genetic variance. Despite some well-
documented evidence from endemic areas, the advancement
in epidemiological understanding in nonendemic areas espe-
cially Northern European countries has been particularly
difficult.This is probably one of themost perplexing problems
and reflects a lack of detailed epidemiological studies in the
so-called nonendemic regions across the globe.
BD is generally described as a polygenic disease; however,
family clustering in BD has been described in the literature
[181–185]. There is an aberrant subset of BD that carries
autosomal-dominant traits highlighting a different pathway
in disease pathogenesis. Several candidate gene mutations
have been discovered so far including MEFV/TLR4 muta-
tions [186] and more recently TNFAIP3 mutations [187, 188]
suggesting several different possible underlying mechanisms
to induce inflammation from these mutations including the
more recent concept of haploinsufficiency of A20 (HA20)
[189]; however, data are still scarce and limited. Targeted
next-generation exome sequencing which has the ability to
generate millions of short reads of sequence within a short
period of time looks promising in novel gene discovery
and may provide answers to many questions in the future
including how broad these spectrum of disorders are and
if there are many other mutations that can cause similar
phenotypic picture.
While nonbiological DMARD agents such as thalido-
mide, methotrexate, azathioprine, and cyclosporine may
provide some benefit to these patients, they carry a higher
side-effect profile. In this cutting edge era, interferon alfa-
2a and TNF have been proven in many instances to be
more effective and safer. Newer treatment paradigms show-
ing promising results include ustekinumab, canakinumab,
apremilast, tocilizumab (especially in neuro-BD), and bro-
dalumab (for severe mucocutaneous manifestations) and
many are undergoing clinical trials. Gevokizumab despite
failing to achieve its primary endpoint, which was time to
a first ocular exacerbation in a phase III study, may still be
effective in preservation of visual acuity, inducing less severe
exacerbations and lower incidence of macula edema, and
is currently undergoing 2 further trials. However, access to
biological agentsmay be the limiting factor inmany countries
and it will be important to identify patients who may be
resistant to certain therapies and those who will benefit
the most from a particular intervention. Head-to-head trials
involving the newer and most current agents rather than
placebo-controlled should be undertaken in patients with
systemic disease or with vital-organ involvement due to
the known grave irreversible consequences in untreated or
inadequately treated patients.
A question that has been long debated is whether or not
to anticoagulate patients with vascular thrombosis. So far,
the decision regarding the use of concomitant anticoagula-
tion with the more definitive glucocorticoids and immuno-
suppressive treatment is based upon individual consultant
opinion and retrospective studies [190]. Due to the paucity
of evidence, and until randomized controlled trial tests the
efficacy of anticoagulation strategies, this question remains
unanswered [190]. Caution is needed especially in the rare
yet lethal condition known as Hughes-Stovin syndrome
where patients have a combination of pulmonary artery
aneurysm and deep vein thrombosis. Immunosuppressive
therapy remains the mainstay of treatment in vascular BD
to induce remission, prevent further relapse, and improve
patients’ survival.
Pregnancy can pose a major challenge in BD as the
evidence regarding the effect of BD on pregnancy and vice
versa is limited. The disease course varies and is difficult to
predict during pregnancy [191–193]. Despite a study demon-
strating a lower proportion of flares in pregnant BD patients
treated with colchicine [194] and another study observing
no increased rate of pregnancy-related complications in BD
patients [194, 195], several other studies have demonstrated
higher miscarriage rates [196, 197], caesarian section rates
[196], and smaller babies [197] in BDpatients. Other potential
issues should also be addressed in pregnancy and in partic-
ular the management of pregnant BD patients with known
thrombotic tendencies.
In this review, we highlight recent advances in our
scientific understanding of BD and shed new insights into
diagnostic and treatment strategies. Despite the increase in
published scientific literature on BD and the growing interest
of a global research community, many aspects of BD remain
enigmatic and controversial. Ironically, these deficits in our
knowledge serve as a stimulus and challenge to the global sci-
entific community to seek answers to these research questions
through national and international collaborations. There is a
pressing need for international epidemiological studies of BD
with geographical and ethnic mapping, more basic science
discoveries to unravel the complex immunopathogenesis,
innovation in biomarker discovery to improve diagnos-
tic yield, and large-scale randomized controlled trials to
assess therapeutic benefit of current and emerging therapies.
Behc¸et’s disease, the Silk Road disease, has challenged the
scientific and clinical communities to come together with a
cohesive strategy to foster greater understanding of this rare
disease in order to improve patient outcomes.
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